119 HR 4273 IH: Over-the-Counter Monograph Drug User Fee Amendments
U.S. House of Representatives
2025-07-02
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
I
119th CONGRESS
1st Session
H. R. 4273
IN THE HOUSE OF REPRESENTATIVES
July 2, 2025
Mr. Latta (for himself, Ms. DeGette, Mr. Crenshaw, and Mrs. Dingell) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.
1.

Short title
This Act may be cited as the “Over-the-Counter Monograph Drug User Fee Amendments”.
2.

Finding
Congress finds that the fees authorized by the amendments made in this Act will be dedicated to OTC monograph drug activities, as set forth in the goals identified for purposes of part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–71 et seq.), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate, as set forth in the Congressional Record.
3.

Definitions
Section 744L(9)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–71(9)(A)) is amended—
(1)
in clause (v), by striking “; or” and inserting a semicolon;
(2)
in clause (vi)—
(A)
by striking “addition” and inserting “the addition”; and
(B)
by striking the period and inserting “; or”; and
(3)
by adding at the end the following:
“(vii)
the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is—
(I)
established by a national or international standards development organization; and
(II)
recognized by the Secretary through a process described in guidance for industry, initially published in July 2023, or any successor guidance, publicly available on the agency website, which addresses voluntary consensus standards for pharmaceutical quality.”.
4.

Authority to assess and use OTC monograph fees
(a)

Types of fees
Section 744M(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–72(a)(1)) is amended—
(1)
in subparagraph (A)—
(A)
by striking “on December 31 of the fiscal year or at any time during the preceding 12-month period” and inserting “at any time during the applicable period specified in clause (ii) for a fiscal year”;
(B)
by striking “Each person” and inserting the following:
“(i)

Assessment of fees
Each person”; and
(C)
by adding at the end the following:
“(ii)

Applicable period
For purposes of clause (i), the applicable period is—
(I)
for fiscal year 2026, the 12-month period ending on December 31, 2025;
(II)
for fiscal year 2027, the 9-month period ending on September 30, 2026; and
(III)
for fiscal year 2028 and each subsequent fiscal year, the 12-month period ending on September 30 of the preceding fiscal year.”;
(2)
in subparagraph (B)(i), by amending subclause (I) to read as follows:
“(I)
has ceased all activities related to OTC monograph drugs prior to—
- (aa)
for purposes of fiscal year 2026, January 1, 2025;
- (bb)
for purposes of fiscal year 2027, January 1, 2026; and
- (cc)
for purposes of fiscal year 2028 and each subsequent fiscal year, October 1 of the preceding fiscal year; and”; and
(3)
by amending subparagraph (D) to read as follows:
“(D)

Due date
(i)

Fiscal year 2026
For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of—
(I)
the first business day of June of such year; or
(II)
the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year.
(ii)

Fiscal year 2027
For fiscal year 2027, the facility fees required under subparagraph (A) shall be due—
(I)
in a first installment representing 50 percent of such fee, on the later of—
- (aa)
October 1, 2026; or
- (bb)
the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year; and
(II)
in a second installment representing the remaining 50 percent of such fee, on—
- (aa)
February 1, 2027; or
- (bb)
if an appropriations Act described in subclause (I)(bb) is not in effect on February 1, 2027, the first business day after enactment of such an appropriations Act.
(iii)

Subsequent fiscal years
For fiscal year 2028 and each subsequent fiscal year, the facility fees required under subparagraph (A) shall be due on the later of—
(I)
the first business day on or after October 1 of the fiscal year; or
(II)
the first business day after the date of enactment of an appropriations Act providing for the collection and obligation of fees under this section for the fiscal year.”.
(b)

Fee revenue amounts
Section 744M(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–72(b)) is amended to read as follows:
“(b)

Fee revenue amounts
(1)

In general
For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—
(A)
the annual base revenue for the fiscal year (as determined under paragraph (2));
(B)
the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1));
(C)
the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(2));
(D)
additional direct cost adjustments (as determined under subsection (c)(3));
(E)
an additional dollar amount equal to—
(i)
$2,373,000 for fiscal year 2026;
(ii)
$1,233,000 for fiscal year 2027; and
(iii)
$854,000 for fiscal year 2028; and
(F)
in the case of a fiscal year for which the Secretary applies the one-time facility fee workload adjustment under subsection (c)(4), the dollar amount equal to such adjustment.
(2)

Annual base revenue
For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be—
(A)
for fiscal year 2026, the dollar amount of the total revenue amount established for fiscal year 2025 under this subsection as in effect on the day before the date of enactment of the Over-the-Counter Monograph Drug User Fee Amendments, not including any adjustments made for such fiscal year 2025 under subsection (c)(2), as so in effect; and
(B)
for fiscal years 2027 through 2030, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made for such previous fiscal year under subsection (c)(2) or (c)(3).”.
(c)

Adjustments; annual fee setting
Section 744M(c) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–72) is amended—
(1)
in paragraph (1)—
(A)
in subparagraph (A), in the matter preceding clause (i)—
(i)
by striking “subsection (b)(2)(B)” and inserting “subsection (b)(1)(B)”; and
(ii)
by striking “fiscal year 2022 and each subsequent fiscal year” and inserting “each fiscal year”;
(B)
in subparagraph (B), by striking “fiscal year 2022” and all that follows through the period at the end and inserting the following:
“a fiscal year shall be equal to the product of—
(i)
for fiscal year 2026—
(I)
the fee for fiscal year 2025 under subsection (a)(2); and
(II)
the inflation adjustment percentage under subparagraph (C); and
(ii)
for each of fiscal years 2027 through 2030—
(I)
the applicable fee under subsection (a)(2) for the preceding fiscal year; and
(II)
the inflation adjustment percentage under subparagraph (C).”; and
(C)
in subparagraph (C)—
(i)
in the matter preceding clause (i), by inserting “the sum of” after “is equal to”;
(ii)
by striking clause (i);
(iii)
by redesignating subclauses (I) and (II) as clauses (i) and (ii), respectively, and adjusting the margins accordingly;
(iv)
by striking “(ii) for each of fiscal years 2024 and 2025, the sum of”; and
(v)
in clause (ii), as so redesignated, by striking “Washington-Baltimore, DC–MD–VA–WV” and inserting “Washington–Arlington–Alexandria–DC–VA–MD–WV”;
(2)
in paragraph (2)—
(A)
in subparagraph (A)—
(i)
by striking “fiscal year 2021 and subsequent fiscal years” and inserting “each fiscal year”;
(ii)
by striking “subsections (b)(1)(B) and (b)(2)(C)” and inserting “subsection (b)(1)(C)”; and
(iii)
by striking “the number of weeks specified in subparagraph (B)” and inserting “10 weeks”;
(B)
by striking subparagraph (B);
(C)
by redesignating subparagraphs (C) and (D) as subparagraphs (B) and (C), respectively; and
(D)
in subparagraph (C), as so redesignated, by striking “paragraph (4) establishing” and inserting “paragraph (5) publishing”;
(3)
in paragraph (3)—
(A)
in the matter preceding subparagraph (A), by striking “subsection (b)(2)(D)” and inserting “subsection (b)(1)(D)”; and
(B)
by striking subparagraphs (A) through (E) and inserting the following:
“(A)
$135,000 for fiscal year 2026;
(B)
$300,000 for fiscal year 2027;
(C)
$55,000 for fiscal year 2028;
(D)
$0 for fiscal year 2029; and
(E)
$30,000 for fiscal year 2030.”; and
(4)
by striking paragraph (4) and inserting the following:
“(4)

One-time facility fee workload adjustment
(A)

In general
In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance with this paragraph.
(B)

Adjustment described
(i)

Conditions for adjustment
An adjustment under this paragraph may be made for a fiscal year only if—
(I)
an adjustment under this paragraph had not been made for any prior fiscal year;
(II)
the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the period of the preceding 3 fiscal years exceeds 1,625; and
(III)
with respect to facilities described in subclause (II), the average number of such facilities (expressed as a percentage) that appeared on the arrears lists pursuant to subsection (e)(1)(A)(i) over the period of the preceding 3 fiscal years is less than 30 percent.
(ii)

Amount of adjustment
An adjustment under this paragraph for a fiscal year shall equal the product of—
(I)
the total facility revenue amount determined under subsection (b) for the fiscal year, exclusive of the adjustment under this paragraph for such fiscal year; and
(II)
the excess facility percentage described in clause (iii).
(iii)

Excess facility percentage
The excess facility percentage described in this clause is—
(I)
the amount by which the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the preceding 3 fiscal years exceeds 1,625; divided by
(II)
1,625.
(5)

Annual fee setting
The Secretary shall, not later than 60 days before the first day of each fiscal year—
(A)
establish for such fiscal year, based on the revenue amounts under subsection (b) and the adjustments provided under this subsection—
(i)
OTC monograph drug facility fees under subsection (a)(1); and
(ii)
OTC monograph order request fees under subsection (a)(2); and
(B)
publish such fee revenue amounts, facility fees, and OTC monograph order request fees in the Federal Register.”.
(d)

Crediting and availability of fees
Section 744M(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–72(f)) is amended—
(1)
in paragraph (2)(D)—
(A)
in the subparagraph heading, by striking “in subsequent years”; and
(B)
by striking “(after fiscal year 2021)”; and
(2)
in paragraph (3), by striking “2021 through 2025” and inserting “2026 through 2030”.
5.

Reauthorization; reporting requirements
Section 744N of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–73) is amended—
(1)
in subsection (a)—
(A)
by striking “Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter” and inserting “Not later than 120 calendar days after the end of each fiscal year”; and
(B)
by striking “section 3861(b) of the CARES Act” and inserting “section 2 of the Over-the-Counter Monograph Drug User Fee Amendments”;
(2)
in subsection (b), by striking “fiscal year 2021 and each subsequent fiscal year” and inserting “each fiscal year”; and
(3)
in subsection (d), by striking “2025” each place it appears and inserting “2030”.
6.

Sunset dates
(a)

Authorization
Sections 744L and 744M of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–71; 379j–72) shall cease to be effective October 1, 2030.
(b)

Reporting requirements
Section 744N of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–73) shall cease to be effective January 31, 2031.
7.

Effective date
The amendments made by this Act shall take effect on October 1, 2025, or the date of the enactment of this Act, whichever is later, except that fees under part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–71 et seq.) shall be assessed beginning October 1, 2025, regardless of the date of the enactment of this Act.
8.

Savings clause
Notwithstanding the amendments made by this Act, part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–71 et seq.), as in effect on the day before the date of enactment of this Act, shall continue to be in effect with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2026.